Because hope is in your hands, we leave nothing to chance.
Boston Scientific is committed to unlocking the full potential of Interventional Oncology technologies and empower you to choose the best treatment for each patient.
This year, we supported a great initiative aimed at showing support to the European Liver Patient Association (ELPA).
Many physicians drove the conversation and helped us supporting ELPA by telling us what they believe is key to a better future for cancer patients.
Satellite Symposium On-Demand
Prof. Guiu presented PROACTIF, the largest, multi-centre, prospective study on primary liver cancer treated with TheraSphere Y-90 generating real-world evidence in 1,000+ patients.
Watch his presentation here:
Prof. de Kerviler presented the results of EuRECA, a prospective, multi-centre study aimed at evaluating the safety, efficacy, and renal function preservation of cryoablation for small renal masses (SRMs) in inherited RCC syndromes.
Watch his presentation here:
Best at ECIO Session
Prof. Etienne Garine presented an oral abstract presentation on Treatment of intrahepatic cholangiocarcinoma with Y-90 glass microspheres in the PROACTIF study. Watch his presentation here.
Join Prof. Etienne Garin as he will dive into the presentation on Treatment of intrahepatic cholangiocarcinoma with Y-90 glass microspheres in the PROACTIF Study.
TheraSphereTM NOW: Online ordering platform
Discover TheraSphere NOW, the online portal designed to seamlessly facilitate your Y90 glass microspheres order placement and track the delivery status in real time – all in one place!
Access now the new ordering platform
IceSeed 1.5 CX and 1.5 CX Short Cryoablation Needles
Now available, the IceSeed Needles have a sharp unibody tip assuring confident insertion, a small&flexible tubing to limit needle movement and a narrow profile allowing multiple needles placement.
Everything for a precise control of procedure.
Thanks to the shorter shaft length combined with the smaller, the IceSeed CX needles allow you to have flexibility and precise control of treatments for:
- benign or malignant tumors
- cryoneurolysis
- small or superficial lesions.